• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Strategy for development of inhibitors targeting PRMT5 for promoting synthetic lethality

Research Project

Project/Area Number 21K07128
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 50010:Tumor biology-related
Research InstitutionSaitama Medical University (2022-2023)
University of Miyazaki (2021)

Principal Investigator

Ichikawa Tomonaga  埼玉医科大学, 医学部, 講師 (80586230)

Project Period (FY) 2021-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2023: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2022: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2021: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
KeywordsPRMT5 / NDRG2 / HSP90 / ATL / がん / synthetic lethality
Outline of Research at the Start

新規がん抑制遺伝子NDRG2発現低下は高リン酸化PRMT5に依存したHSP90Aアルギニンメチル化修飾を引き起こす。HSP90Aアルギニンメチル化によるシャペロン活性亢進がクライアントタンパク質を安定化させATLがん発症進展に繋がっていた。PRMT5発現抑制すると細胞死を誘導したが、NDRG2発現正常細胞ではこの現象が出現しないことから、NDRG2発現低下ATLがん細胞のみで特異的に細胞死させる合成致死性(Synthetic lethality)を発見した。そこで本研究は合成致死性を介したNDRG2欠損がん特異的なPRMT5酵素活性に依存したHSP90を標的とした新規阻害剤の創出を目的とする。

Outline of Final Research Achievements

A novel tumor suppressor N-Myc downstream-regulated gene 2 (NDRG2) is frequently downregulated in many types of tumors, including adult T-cell leukemia/lymphoma (ATL). The loss of NDRG2 expression is involved in aberrant activation of signal transduction pathways through continuous phosphorylation of several signaling molecules, leading to tumor progression. Furthermore, we identified cytoplasmic and hyperphosphorylated protein arginine methyltransferase 5 (PRMT5) associates with abnormal protein arginine methylation in NDRG2low ATL. We found that the suppression of PRMT5, and binding partner expression or the inhibition of enzymatic activity remarkably induces synthetic lethality followed by cell death in NDRG2low ATL. Therefore, the purpose of this study is to analyze the mechanism of synthetic lethality and to lead to a feasible and effective strategy for development of specific inhibitors that targets PRMT5 enzymatic activity for promoting synthetic lethality in NDRG2low cancers.

Academic Significance and Societal Importance of the Research Achievements

NDRG2発現低下によってストレス応答の恒常性維持機構が破綻し、慢性炎症、異常な情報伝達系および翻訳後修飾の亢進が惹起され、腫瘍発症進展、予後不良、薬剤抵抗性および生存率低下に関与している。そのため、NDRG2欠損がん細胞で特異的に「合成致死」を引き起こすPRMT5阻害を標的とした阻害剤はがんに特異的に効果を発揮し、NDRG2発現が保たれる正常細胞では影響を回避できる可能性が高い。また、検索しようとしている阻害剤は細胞質でのPRMT5阻害効果であり、作用点の違う細胞表面を標的とする抗体、分子標的薬や核内を標的する阻害剤と併用することで容量の低減や副作用の軽減に繋がる可能性がある。

Report

(4 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • Research Products

    (14 results)

All 2024 2023 2022 2021

All Journal Article (8 results) (of which Int'l Joint Research: 8 results,  Peer Reviewed: 8 results,  Open Access: 8 results) Presentation (4 results) Book (2 results)

  • [Journal Article] IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors2024

    • Author(s)
      Wang Yu、Shimosaki Shunsuke、Ikebe Emi、Iha Hidekatsu、Yamamoto Jun-ichi、Fife Nichole、Ichikawa Tomonaga、Hori Mitsuo、Ogata Masao、Tsukamoto Yoshiyuki、Hijiya Naoki、Moriyama Masatsugu、Hagiwara Shotaro、Kusano Shuichi、Saito Masumichi、Ahmed Kamruddin、Nishizono Akira、Handa Hiroshi、Morishita Kazuhiro
    • Journal Title

      Frontiers in Oncology

      Volume: 13 Pages: 01-13

    • DOI

      10.3389/fonc.2023.1272528

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Inhibition of adult T-cell leukemia cell proliferation by polymerized proanthocyanidin from blueberry leaves through JAK proteolysis.2022

    • Author(s)
      Ichikawa T, Sugamoto K, Matsuura Y, Kunitake H, Shimoda K, Morishita K.
    • Journal Title

      Cancer Science

      Volume: 113 Issue: 4 Pages: 1406-1416

    • DOI

      10.1111/cas.15277

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] The CGRP Receptor Antagonist MK0974 Induces EVI1 high AML Cell Apoptosis by Disrupting ERK Signaling.2022

    • Author(s)
      Suekane A, Ichikawa T, Saito Y, Nakahata S, Morishita K.
    • Journal Title

      ANTICANCER RESEARCH

      Volume: 42 Pages: 4743-4752

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Oncogenic isoform switch of tumor suppressor BCL11B in adult T-cell leukemia/lymphoma.2022

    • Author(s)
      Permatasari HK, Nakahata S, Ichikawa T, Fauzi YR, Kiyonari H, Shide K, Kameda T, Shimoda K, Ono M, Taki T, Taniwaki M, Futakuchi, Morishita K.
    • Journal Title

      Experimental Hematology

      Volume: 111 Pages: 41-49

    • DOI

      10.1016/j.exphem.2022.04.004

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Integrin α6A (ITGA6A)-type Splice Variant in Extracellular Vesicles Has a Potential as a Novel Marker of the Early Recurrence of Pancreatic Cancer.2022

    • Author(s)
      Asada T, Nakahata S, Fauzi YR, Ichikawa T, Inoue K, Shibata N, Fujii Y, Imamura N, Hiyoshi M, Nanashima A, Morishita K.
    • Journal Title

      ANTICANCER RESEARCH

      Volume: 42 Issue: 4 Pages: 1763-1775

    • DOI

      10.21873/anticanres.15653

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Role of Mel1/Prdm16 in bone differentiation and morphology2022

    • Author(s)
      Kaneda-Nakashima Kazuko、Igawa Kaori、Suwanruengsri Mathurot、Naoyuki Fuke、Ichikawa Tomonaga、Funamoto Taro、Kurogi Shuji、Sekimoto Tomohisa、Yamashita Yoshihiro、Chosa Etsuo、Yamaguchi Ryoji、Morishita Kazuhiro
    • Journal Title

      Experimental Cell Research

      Volume: 410 Issue: 2 Pages: 112969-112969

    • DOI

      10.1016/j.yexcr.2021.112969

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Antitumor effects of chloroquine/hydroxychloroquine mediated by inhibition of the NF-κB signaling pathway through abrogation of autophagic p47 degradation in adult T-cell leukemia/lymphoma cells.2021

    • Author(s)
      Fauzi YR, Nakahata S, Chilmi S, Ichikawa T, Nueangphuet P, Yamaguchi R, Nakamura T, Shimoda K, Morishita K.
    • Journal Title

      PLoS One

      Volume: 16 Issue: 8 Pages: e0256320-e0256320

    • DOI

      10.1371/journal.pone.0256320

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Pathophysiological significance of NDRG2 in cancer development through PP2A phosphorylation regulation.2021

    • Author(s)
      Morishita K, Nakahata S, Ichikawa T.
    • Journal Title

      Cancer Sci

      Volume: 112 Issue: 1 Pages: 22-30

    • DOI

      10.1111/cas.14716

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] Interference with MEP50 inhibits HSP90 function and tumor development in NDRG2low adult T-cell leukemia.2023

    • Author(s)
      Tomonaga Ichikawa, Kazuhiro Morishita, Akihiro Nakamura, Yutaka Horiuchi, Takashi Murakami.
    • Organizer
      第82回日本癌学会
    • Related Report
      2023 Annual Research Report
  • [Presentation] Analysis of the constitutive activation of Jak/STAT signaling pathway through the loss of tumor suppressor gene NDRG2.2022

    • Author(s)
      Tomonaga Ichikawa
    • Organizer
      第81回日本癌学会
    • Related Report
      2022 Research-status Report
  • [Presentation] Development of the treatment for adult T cell leukemia/lymphoma (ATL) by highly polymerized proanthocyanidins from blueberry leaves.2021

    • Author(s)
      Tomonaga Ichikawa
    • Organizer
      第94回日本生化学会
    • Related Report
      2021 Research-status Report
  • [Presentation] Treatment of ATL via proteasomal degradation of JAK by highly polymerized proanthocyanidins from blueberry leaves.2021

    • Author(s)
      Tomonaga Ichikawa
    • Organizer
      第80回日本癌学会
    • Related Report
      2021 Research-status Report
  • [Book] Medical Science Digest2021

    • Author(s)
      市川朝永、森下和広
    • Total Pages
      2
    • Publisher
      ニュー・サイエンス社
    • Related Report
      2021 Research-status Report
  • [Book] 月刊「細胞」2021

    • Author(s)
      市川朝永、森下和広
    • Total Pages
      4
    • Publisher
      ニュー・サイエンス社
    • Related Report
      2021 Research-status Report

URL: 

Published: 2021-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi